Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics”…
Month: May 2023
Faraday Future Kicks Off Nine-Day Countdown Campaign as it Approaches the FF 91 Final Launch & Faraday Future 2.0 Event on May 30, 2023
LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (Nasdaq: FFIE) (“Faraday Future”, “FF” or “Company”), a…
Seraphic Security Named as a 2023 SC Awards Finalist
Seraphic’s First of its Kind Enterprise Browser Security Solution Recognized as Outstanding Best Threat Detection…
Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
Completes Business Combination and Becomes Publicly Traded Company Third Quarter Fiscal 2023 Net Revenues Totaled…
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in…
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in…
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
Posting of Annual Report & Notice of AGM
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
Posting of Annual Report & Notice of AGM
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…